Background. The incarceration rate has increased 239% in the United States over the past 2 decades. This increase in incarceration has been fueled by the movement towards a criminal, rather than medical, response to the problem of drug dependence. For women in particular, incarceration and drug use are interdependent epidemics. Given that incarceration is common among drug-dependent persons, infectious diseases-including hepatitis B virus (HBV) and hepatitis C virus (HCV) infection-are prevalent among incarcerated persons. We sought to determine the incidence of HBV and HCV infection among recidivist women prisoners.
In the past 2 decades, there has been an epidemic of incarceration in the United States; currently, 2 million people are incarcerated, an increase of 239% over the past 2 decades [1] . In 2000, a total of 0.7% of US residents were incarcerated in state or federal prisons or local jails [2] . This increase in incarceration has been fueled by the movement in recent years towards a criminal, rather than medical, response to the problem of drug dependence. Inmates sentenced for a drug offense accounted for 15% of the population growth in state prisons and almost one-half (48%) of the population growth in federal prisons [3] . One-fifth of state prisoners and 55% of federal prisoners are incarcerated for using, possessing, or trafficking drugs [3] . Given that incarceration is common among drug-dependent persons, infectious diseases-including hepatitis B virus (HBV) and hepatitis C virus (HCV) infection-are prevalent among incarcerated persons. Incarcerated persons report more injection drug use and unsafe sexual practices than does the population at large [4] . A study conducted by the Centers for Disease Control and Prevention (CDC) of 231 individuals with acute HBV infection found that 29% of them had a history of incarceration [5] . Past prevalences of HBV infection among inmates in certain states range from 19% in Wisconsin [6] to 29% in Tennessee [7] and 47% in New Mexico [8] . Although the overall national prevalence of HCV infection is 1.8%, studies in certain highrisk populations (e.g., homeless persons, incarcerated persons, and injection drug users) have found preva-lences ranging from 15% to 90% [9] . Reported prevalences of HCV infection among prisoners range from 27% to 49% [10] [11] [12] .
For women in particular, incarceration and drug use are interdependent epidemics. Women are more likely than men to be serving sentences for drug offenses [2] . Seventy-four percent of female inmates in federal and state prisons have ever used drugs regularly [13] . Female inmates are more likely than are male inmates to have used drugs and to have been under the influence at the time of the offense [14] . Women are also more likely than men to have committed crimes to obtain money for drugs [14] . Ninety percent of the women in the Rhode Island Department of Corrections are incarcerated for drug use, prostitution, or both [15] . Prevalence of hepatitis viruses among female inmates is consistently higher than it is among male inmates [11] [12] , which is the reverse of what is observed in the general population.
Most studies of incidence in these populations have focused on incidence that occurs while individuals are incarcerated [8, [16] [17] [18] [19] [20] . However, turnover rates among offenders and former offenders are extremely high-1300% in jails and 40% in prisons [25] [26] -demonstrating the permeability of the barrier between correctional facilities and the civilian community. The first several weeks after release from prison or jail are associated with high risk; among other things, the prevalence of overdose and of high-risk sexual behavior are increased [21] [22] [23] [24] . For populations cycling in and out of correctional facilities, this high-risk period recurs again and again with each incarceration. Therefore, we sought to examine the prevalence and incidence of HBV and HCV infection among recidivists.
METHODS

Study setting.
The Rhode Island Department of Corrections operates from a single site, serving as both a jail for those awaiting trial and a prison for sentenced individuals. The correctional facility processes ∼15,000 intakes per year, 3000 of whom are women. The prison's average daily female census during the study period was 193 persons. On intake to the prison, the median age was 32 years, and the racial/ethnic distribution was as follows: 71% white, 21% black, and 6% Hispanic. The median length of sentence was 8 months.
In 1988, the state of Rhode Island enacted a law requiring all inmates to undergo a confidential HIV test after sentencing. Because all inmates undergo a brief medical assessment on intake to the prison, regardless of sentencing, most (90%) of arrested individuals undergo HIV testing on intake. Individuals may not be tested on intake for various reasons: refusal to be tested (legally allowed if a person is not sentenced), difficulty in obtaining blood, recent incarceration (for which a recent HIV test result exists), and, occasionally, previous determination of HIV infection status by prison medical personnel. Also, on intake to the prison, all inmates undergo a "medical entrance screen," during which medical staff record an inmate's status regarding "drug or alcohol abuse," "IV drug use," and "venereal disease," among other things, by means of yes/no check-boxes.
Study design.
From January 1996 through November 1997, excess serum samples obtained from all HIV-tested incoming inmates were collected and stored. Occasionally, samples were discarded inadvertently by laboratory staff in a random fashion, and, as described above, not all incoming inmates were tested. In addition, excess serum samples were not available for those inmates who tested positive for HIV infection, because the serum samples were required for confirmatory HIV testing. Serum samples were linked to demographic variables (age and race), as well as to standard medical intake data, including self-reported histories of hepatitis, sexually transmitted disease, drug and/or alcohol type and use, injection drug use, and high-risk sexual practices and history of blood transfusions ascertained by chart review. We defined recidivist women as women who were incarcerated and had undergone initial medical assessment at the intake facility multiple times during our study period. Multiple samples obtained from single individuals who were incarcerated multiple times during the study period were matched and study identification was assigned. Names and unique identifiers were removed prior to testing.
Prevalence was estimated for recidivist women. We were able to determine the incidence of HBV and HCV infection among recidivist women by comparing their serostatus on intake for multiple incarcerations. We also sought to attribute this incidence to risk that occurred in either the community or while incarcerated by evaluating the time period between incarcerations. The protocol was approved by the Miriam Hospital Human Subjects Committee, which included a prisoner advocate.
Analysis. Prevalence of HBV and HCV infection was estimated for all incoming HIV-seronegative women. Incidence among reincarcerated women was determined by testing the first and last available intake samples obtained from HIVuninfected recidivist women. Incidence was calculated using person-year analyses. The number of person-years was counted between the first and last dates of intake for recidivists during the study period.
Univariate analyses were performed to determine factors that correlated with each incidence of infection. Multivariate logistic regression was conducted to further delineate the variables that remained significant predictors of seropositivity when other variables, such as age, race, previous incarceration, drug or alcohol use, injection drug use, and high-risk sexual activities were controlled. The dependent variables in the logistic regression models were incidence of infection (for HIV, HBV, and HCV infection), whereas the independent variables were potential infection correlates (e.g., age and race). Age was di- chotomized into 2 variables (!25 years and у25 years) because of the higher risk associated with these infections reported in younger subjects. All analyses were performed using EpiInfo (Centers for Disease Control and Prevention) and Stata (Stata) statistical software. Laboratory testing. Testing for HBV infection was done by ELISA (Corzyme EIA; Abbott Laboratories). Inmates were considered to be HBV seropositive if a sample of their serum tested positive for antibody to hepatitis B core. Testing for HCV infection was done with the Ortho HCV Version 3.0 ELISA Test System (Ortho-Clinical Diagnostics). In all cases, initially reactive samples were retested in duplicate for accuracy.
RESULTS
From January 1996 through November 1997, a total of 2006 women were incarcerated. Of those, 526 individuals were released and reincarcerated during that time, and 297 had available excess serum samples; thus, our study population was limited to the 297 women for whom sera was available. Age and racial/ethnic distributions did not differ between our study population of 297 women and the total recidivist population of 527 women (30.9 years vs. 30 Risk behavior and demographic characteristics are outlined in table 1. The group was approximately two-thirds white, and the mean age was ∼30 years old. The most commonly reported risk factor was drug and/or alcohol use. A large proportion of women had histories of previous incarceration in Rhode Island. Table 2 outlines the seroincidence, stratified by demographic characteristics. Both HBV and HCV seroconversion were strongly associated with a reported history of heroin and/or injection drug use. Incidence of both viruses was also associated with white race, although not as strongly.
The average time period between first and last incarcerations was 302 days. Of these 302 days, a mean of 219 days (72.5%) was spent in the community and a mean of 83 days (27.5%) was spent incarcerated.
DISCUSSION
This is, to our knowledge, the first study in the United States to estimate the incidence of HBV and HCV infection among women using multiple samples obtained from the same individuals on intake to an incarceration facility. Because the recidivists included in our study were in the community 170% of the time between incarcerations, we attributed incident infection primarily to high-risk behaviors that occurred in the community.
The community incidence of HBV and HCV infection among reincarcerated women in Rhode Island is, as we have described here, extremely high. In fact, it is many times higher than the intraprison incidence that we have outlined elsewhere [19] among male prisoners (2.7 and 0.4 cases of HBV and HCV infection per 100 person-years, respectively). If the rate of HBV and HCV infection during incarceration is low and the incidence among previously incarcerated individuals in the community is high, then prison may be viewed as a lowerrisk stopover in the cycle from prison to the community. Annual turnover rates are 1300% for jail inmates and 40% for prison inmates [25] [26] , and during 1997, 20%-26% of all people infected with HIV and 29%-43% of all people infected with HCV in the United States passed through a correctional facility [27] . Time spent in an incarcerated facility, which often punctuates a time period of higher risk spent in the community, provides an important opportunity for public health interventions.
Key interventions in prisons and jails include vaccination for HBV [25, [28] [29] [30] , HCV testing and counseling-including education about cessation of alcohol use for HCV-infected inmates [25, 28] -and linkage to medical and drug treatment services, including methadone treatment, on release [15, 31] . Even 1 dose of the HBV vaccine during their first incarceration could have protected up to 50% of the women in our study sample from this vaccine-preventable disease [32] . Although the United States has implemented universal childhood vaccination for HBV, most adults at high risk remain unvaccinated [5, 29] . Numerous successful programs addressing diagnosis, treatment, and prevention of HBV and HCV infection have been implemented in incarceration facilities [31, [33] [34] . For many individuals, their first adult contact with a health care provider occurs while they are incarcerated [35] . The limitations of this study include the bias introduced by sampling only non-HIV-infected women. Given overlapping risk factors between HIV infection and viral hepatitis, we are probably underestimating the prevalence and incidence of HBV and HCV infection among recidivist women. However, given the relatively low prevalence of HIV infection in this group (2.4%), the impact of this is probably modest. On the other hand, those women who become reincarcerated are likely to be women at highest risk, because reincarceration may be a marker for ongoing risk behavior. Although the data are almost 10 years old, the current situation may be worse, given the ever-expanding number of incarcerated persons. In addition, we are unable to say with certainty whether infection occurred in the community or in the correctional facility. It takes 30-60 days for markers of HBV and HCV infection to appear in serum [36] [37] , so it is possible that infections acquired during a previous incarceration would not become apparent until a subsequent incarceration.
A recent CDC publication [38] reports that, after a decade of decreasing, the incidence of HBV infection among men aged 119 years and women aged у40 years has increased, primarily because of poor vaccination among persons known to be at high risk. Almost one-third of persons with acute HBV infection in the United States report a history of incarceration [30] . The data presented here make it clear that we must address the epidemic of viral hepatitis among incarcerated and formerly incarcerated persons. Perhaps prevention programs in the incarcerated setting would better prepare inmates to protect themselves on release. Given the unfortunate cycle between incarceration facilities and the community, preventing and treating disease in incarceration facilities benefits both prisoners and the public's overall health.
